Consequently, we performed fully connected deep neuronal networks to predict drugs with the highest affinities per target and multi-targets. We identified 45 approved drugs, 16 compounds under investigation, and 35 experimental compounds with the highest AUROCs for 15 immune system proteins (Supplementary Table ). Regarding approved drugs, citicoline (B4GALT1) provides neuroprotection; lanreotide (C3) has been approved for treatment of neuroendocrine tumors and acromegaly; amprenavir, atazanavir, saquinavir, darunavir, fosamprenavir and lopinavir had the highest affinities with CTSD and are employed for treatment of HIV-1 infection; nelfinavir (MAP3K) inhibits the HIV viral proteinase enzyme; rilpivirine (EGFR) is indicated for treatment of HIV-1 infection; aliskiren (CTSD) is a renin inhibitor for arterial hypertension; enzalutamide (CTSS) is an androgen receptor inhibitor that acts as an antineoplastic in prostate cancer; paritaprevir (CTSS) has been approved for treatment of chronic hepatitis C virus infection; zofenopril is an ACE inhibitor and is employed as both a cardioprotective and anti-hypertensive agent; tesamorelin (F2RL1) has been approved for treatment of HIV-infected patients as it is an growth hormone-releasing factor with lipolytic effect; etelcalcetide (F2RL1) is indicated for secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis; clobetasol propionate (HIF1A) is one of the most potent corticosteroids and is employed to treat psoriasis as well as inflammatory manifestations of corticosteroid-responsive dermatoses; topotecan (HIF1A) is an antineoplastic and immunomodulating agent; zanamivir and peramivir (NEU1) are indicated for treatment of influenza A and B; digitoxin (STAT3) is employed for treatment of congestive cardiac insufficiency, arrhythmias, and heart failure; pibrentasvir (STAT3) is indicated for treatment of patients with chronic hepatitis C virus; erlotinib, methotrexate, imatinib, pemetrexed, lapatinib, sunitinib, vandetanib, midostaurin, bosutinib, axitinib, ruxolitinib, afatinib, ibrutinib, and gilterinib had the highest affinities with EGFR and act as antineoplastic and immunomodulating agents; torasemide and triamterene (EGFR) act on cardiovascular system; allopurinol, quinine, and oxaprozin (EGFR) act on musculoskeletal system; cabergoline (EGFR) acts on nervous system; nedocromil (EGFR) acts on respiratory system; fostamatinib (EGFR) is indicated for treatment of chronic immune thrombocytopenia; and duvelisib (EGFR) can produce a broad adaptive and innate immune cell inhibitory activity. Additionally, we identified 4 approved drugs, 9 compounds under investigation, and 16 experimental compounds with the highest multi-target affinities for 9 immune system proteins (Supplementary Table ). Beclomethasone dipropionate (HIF1A and STAT3) is a highly potent glucocorticoid in the airway; rosoxacin (STAT3 and EGFR) is indicated for treatment of bacterial infection of respiratory tract; halofantrine (EGFR and CTSD) is employed for treatment of severe malaria; and, paritaprevir (CTSD, CTSS, and STAT3) is indicated for treatment of hepatitis C virus infection. After these analyses, a broad spectrum of possibilities for co-therapies are expanded; for instance, with drugs directly targeting SARS-CoV-2, including remdesivir 117 .